Iscalimab, a novel anti-CD40 monoclonal antibody, showed efficacy in lupus nephritis (LN) by reducing proteinuria at 24 weeks compared with placebo. The treatment was generally well tolerated, with ...
The field of immunotherapy is facing a revolutionary evolution, with CD40-targeting therapies being one of the most groundbreaking approaches to treating many diseases. Such treatments hold the ...
New York, NY - Researchers have identified a "rare, but informative" mutation on the CD40 gene that may play a role in B-cell activation and autoimmunity in systemic lupus erythematosus (SLE), ...
BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic lupus erythematosus (SLE) get symptoms under control, according ...
The trial met its primary composite endpoint demonstrating significant clinical improvement with dapirolizumab pegol vs placebo in patients with moderate to severe SLE. Topline results were announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results